Reneo Pharmaceuticals, Inc. (RPHM)

1.7100 +0.0400 (+2.40%) At close: 04:00PM EDT

Reneo Pharmaceuticals, Inc.

18575 Jamboree Road
Suite 275-S
Irvine, CA 92612
United States
858 283 0280
https://reneopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael G. Grey	Founder & Executive Chairman	100k	N/A	1953
Mr. Gregory J. Flesher	President, CEO & Director	569.7k	N/A	1970
Dr. Alejandro Dorenbaum M.D.	Chief Medical Officer	466.23k	N/A	1961
Ms. Ashley F. Hall J.D.	Chief Development Officer	447.1k	N/A	1972
Ms. Jennifer P. Lam	SVP of Finance & Administration and Principal Financial & Accounting Officer	N/A	N/A	N/A
Mr. Michael P. Cruse	Chief Operating Officer	535.47k	N/A	1972

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Corporate Governance

Reneo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.